Form 4: Cytosorbents Director Reports Stock Holdings

Cytosorbents Director Alan D. Sobel filed a Form 4 detailing his beneficial ownership of common stock and stock options, including restricted stock units and a new option grant.

Summary

• Alan D. Sobel, a Director of Cytosorbents Corp (CTSO), reported his beneficial ownership of company securities.
• He directly owns 145,757 shares of Common Stock.
• This direct ownership includes 76,457 shares and 69,300 Restricted Stock Units (RSUs) that are set to vest upon a 'Change in Control' event.
• The RSUs were granted on various dates: 3,300 on March 15, 2018; 6,000 on February 24, 2017; 5,000 on June 7, 2016; and 55,000 on April 8, 2015.
• He indirectly owns 2,000 shares of Common Stock through the Bernard Sobel Revocable Trust, where he serves as a trustee and beneficiary.
• He was granted 22,000 stock options on August 8, 2025, with an exercise price of $1.
• These stock options expire on August 8, 2035, and will vest in four equal quarterly installments over one year from the grant date, subject to his continued service.

Sentiment

Score: 7

Explanation: The filing indicates continued insider ownership and a new stock option grant, suggesting alignment of interests between the director and shareholders. It does not contain any negative financial or operational news.

Positives

• Director Alan D. Sobel holds a significant stake in the company, aligning his interests with shareholders.
• The grant of 22,000 stock options to a director indicates continued commitment and incentivizes long-term performance.

Negatives

• No negative information is directly discernible from this ownership report.

Risks

• The vesting of a significant portion of restricted stock units (69,300 RSUs) is contingent upon a 'Change in Control' of the company, which may not occur.

Future Outlook

Stock options granted on August 8, 2025, are set to vest in four equal quarterly installments over one year, contingent on the director's continued service, indicating an expectation of ongoing involvement.

Management Comments

• No specific management comments or strategic statements were included in this filing.

Industry Context

This filing is an insider ownership report and does not contain information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• Not applicable as this filing details individual insider ownership and does not provide company performance metrics for industry comparison.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters were disclosed.

Related Party Transactions

• Alan D. Sobel indirectly holds 2,000 shares of Common Stock through the Bernard Sobel Revocable Trust, for which he is a trustee and a named beneficiary.

Stakeholder Impact

• Shareholders: The director's significant beneficial ownership and new option grant align his interests with shareholder value creation.

Next Steps

• Stock options granted on August 8, 2025, will vest in four equal quarterly installments over the subsequent year.
• Restricted Stock Units will vest upon a 'Change in Control' event.

Key Dates

Recommendation

This Form 4 primarily details a director's beneficial ownership and a new stock option grant, which is a routine insider filing. It does not provide new financial performance data or strategic shifts that would warrant a change in investment recommendation. The continued insider ownership and new grant are generally positive for alignment but do not present a compelling reason for a strong buy or sell.

Keywords

Cytosorbents, CTSO, Form 4, Insider Ownership, Stock Options, Restricted Stock Units, Director Holdings, SEC Filing